Schrödinger Reports Encouraging Phase 1 Data for SGR-1505 in Relapsed/Refractory B-cell Malignancies

June 12, 2025
Schrödinger announced positive initial clinical data from a Phase 1 study of SGR-1505, an oral MALT1 inhibitor, in patients with relapsed/refractory B...